Quest Diagnostics (DGX) Q4 Earnings and Revenues Top Estimates

Core Insights - Quest Diagnostics reported quarterly earnings of $2.23 per share, exceeding the Zacks Consensus Estimate of $2.19 per share, and showing an increase from $2.15 per share a year ago, resulting in an earnings surprise of 1.83% [1] - The company achieved revenues of $2.62 billion for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 1.96%, and up from $2.29 billion year-over-year [2] - Quest Diagnostics has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] Earnings Performance - The earnings surprise for the previous quarter was 1.77%, with actual earnings of $2.30 per share against an expectation of $2.26 per share [1] - The current consensus EPS estimate for the upcoming quarter is $2.21, with expected revenues of $2.61 billion, while the fiscal year estimate is $9.71 on $10.67 billion in revenues [7] Stock Performance and Outlook - Quest Diagnostics shares have increased approximately 3% since the beginning of the year, outperforming the S&P 500's gain of 2.7% [3] - The company's favorable estimate revisions trend prior to the earnings release has resulted in a Zacks Rank 2 (Buy), indicating expected outperformance in the near future [6] Industry Context - The Medical - Outpatient and Home Healthcare industry, to which Quest Diagnostics belongs, is currently ranked in the top 36% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8]